IP18: Stone Disease: Medical & Dietary Therapy
Friday, May 15, 2026 1:00 PM to 3:00 PM · 2 hr. (America/New_York)
147B
Poster and Podium Sessions
Stones
Friday, May 15
IP18-01: A Mouse Model Study on Gene Therapy for Primary Hyperoxaluria Type 3 Using Base Editing Technology
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-02: Dietary factors associated with hyperoxaluria and calcium oxalate supersaturation during long duration spaceflight
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-03: Validation of an AI-Powered Mobile App for Dietary Oxalate and Nutrition Analysis to Support Kidney Stone Prevention
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-04: Urinary supersaturation in a Randomized trial among Individuals with Nephrolithiasis comparing Empiric versus selective therapy (URINE)
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-05: Improvement in 24-hour urine parameters associates with decreased symptomatic kidney stone recurrence
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-06: TRACKING THIAZIDE THERAPY TREATMENT PATTERNS IN RECURRENT STONE FORMERS USING ON-TREATMENT 24-HOUR URINE ANALYSIS
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-07: Within-Patient Change in Stone Composition Over Time Demonstrates Higher Rate of Change in Calcium Phosphate vs. Calcium Oxalate Stones: A Single Center Experience
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-08: Does tap water mineral content correlate with 24-hour urine biochemistry in stone-forming patients? A pilot study in the United Kingdom
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-09: A home device measuring urine quality for preventing recurrent urolithiasis
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-10: Renal Metabolic Defects in Patients with Recurrent Unilateral Nephro- and Ureterolithiasis: Insights from Individual Renal Unit Sampling
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-11: A Validated Artificial Intelligence Model Outperforms Urinary Supersaturation Alone in Predicting Kidney Stone Composition
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-12: Modeling the dissolution rate of uric acid kidney stones during potassium citrate therapy
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-13: Identification of Monosodium Urate Monohydrate Crystal Deposition in Randall’s Plaque Stones from Idiopathic Calcium Oxalate Stone Formers
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-14: Differential effects of dietary sweeteners on kidney stones: results from a prospective cohort study and rat models
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
Zhaohui He
IP18-15: A dietary source of potassium citrate to resolve hypocitraturia and aciduria in patients with a history of nephrolithiasis
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-16: Role and Mechanism of Lipid Metabolism Disorder in Calcium Oxalate Kidney Stone Formation and Targeted Therapeutic Strategies
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
Shushuai Yang
IP18-17: Butyrate-Producing Bacteria and Metabolite Changes in Patients with Kidney Stones
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-18: Risk of urolithiasis and renal protection associated with benzbromarone versus allopurinol: Insights from the trinetx global network
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-19: Chemiluminescence of urine as a predictor of recurrent stone formation
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-20: Dihydromyricetin attenuates the renal damage caused by ureteral obstruction
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-21: Effect of Preoperative Silodosin on Outcomes of Ureteroscopy for Ureterolithiasis: A Systematic Review and Meta-Analysis
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-22: The Effect of Intravenous Administration of a Rho-kinase Inhibitor on Porcine Ureteral Distensibility
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-23: Bisphosphonates for the Management of Nephrolithiasis in High-Risk Stone Forming Patients: A Systematic Review and Meta-Analysis
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-24: Do GLP-1 Receptor Agonists Protect Against Kidney Stones in Diabetes? Real-World Insights
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-25: GLP-1 Agonist Use is Associated with Reduced Risk of Repeat Kidney Stone Events in a Nationally Representative Cohort
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-26: Impact of Glucagon-Like Peptide-1 Receptor Agonists on the Risk and Management of Kidney and Ureteral Stones
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-27: Risk of Stone Formation with Carbonic Anhydrase Inhibitors: A VigiBase Analysis
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B
IP18-28: The Use and Effect of Stone Prophylactic Medications on 24-Hour Urine Chemistry Parameters in Brushite Stone Formers
Friday, May 15, 2026 1:00 PM to 3:00 PM
147B